Clinical Trial Update: Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF) [Phase 2]

View source ↗

Summary

Phase 2 pediatric study evaluating the safety and efficacy of canakinumab in patients with colchicine-resistant or colchicine-intolerant familial Mediterranean …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Mediterranean Fever

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Colchicine Resistant/Intolerant Familial Mediterranean Fever | Phase 2 | Status: COMPLETED